SRT1720 Size:2mg solid 2017 Dec 12

2017 Dec 12

InChiKey: QLUWQAFDTNAYPN-LLVKDONJSA-N

GTS-21 attenuates lipopolysaccharide-induced inflammatory cytokine production in vitro by modulating the Akt and NF-κB signaling pathway through the α7 nicotinic acetylcholine receptor

and then sorted into different compartments

81 μM) by introducing the E3 ligase cereblon (CRBN)-binding ligand pomalidomide to Mcl-1/Bcl-2 dual inhibitor Nap-1

SRT1720 Size:2mg solid 2017 Dec 12SRT 1720, also known as CAY10559 and is a drug developed by Sirtris Pharmaceuticals intended as a small molecule activator of the sirtuin subtype SIRT1. It has similar activity in the body to the known SIRT1 activator resveratrol, but is 1000x more potent. In animal studies it was found to improve insulin sensitivity and lower plasma glucose levels in fat, muscle and liver tissue, and increased mitochondrial and metabolic function. A study of SRT1720